SM-88 | Tyrosine metabolism inhibitor
Available Options
| Size | Price | Quantity | |
|---|---|---|---|
| 10mg | $40.00 | ||
| 50mg | $125.00 |
SM-88 (30625-05-9) is a “dysfunctional” tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4. It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5
References/Citations:
- Lemberg et al. (2022), Clinical development of metabolic inhibitors for oncology; J. Clin. Invest., 132 e148550
- Stega et al. (2020), A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer; Invest. New Drugs, 38 392
- Gartell et al. (2021), Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer; Invest. New Drugs, 39 499
- Noel et al. (2019), Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage J. Clin. Oncol., 37 200
- Brogden et al. (1981), alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use; Drugs, 21 81
C10H13NO3·HCl
>98% TLC
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SM-88 (30625-05-9) is a “dysfunctional” tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4. It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5
References/Citations:
- Lemberg et al. (2022), Clinical development of metabolic inhibitors for oncology; J. Clin. Invest., 132 e148550
- Stega et al. (2020), A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer; Invest. New Drugs, 38 392
- Gartell et al. (2021), Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer; Invest. New Drugs, 39 499
- Noel et al. (2019), Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage J. Clin. Oncol., 37 200
- Brogden et al. (1981), alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use; Drugs, 21 81
Related products
-
Norfluoxetine HCl | Fluoxetine Metabolite
From $60.00CAS:57226-68-3Catalog Number:10-2671Alternate Name:DesmethylfluoxetineActivity:Fluoxetine metaboliteChemical Name:3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine hydrochloride (racemic)Molecular Weight:331.76Molecular Formula:C16H16F3NO HClSolubility:Soluble in DMSO ( up to at least 25 mg/ml)Physical Properties:Beige waxy solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Rucaparib phosphate | PARP1 inhibitor
From $70.00CAS:459868-92-9Catalog Number:10-3321Activity:PARP1 inhibitorChemical Name:8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-oneAlternate Name:AG-14699; PF01367338Molecular Weight:421.36Molecular Formula:C19H18FN3O • H3PO4Solubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.Shipping Code:RT -
Acalabrutinib | Highly selective BTK inhibitor
From $45.00CAS:1420477-60-6Catalog Number:10-4806Alternate Name:ACP-196Activity:Highly selective BTK inhibitorChemical Name:4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamideMolecular Weight:465.52Molecular Formula:C26H23N7O2Solubility:Soluble in DMSO (up to at least 25 mg/ml)Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
20% OFF
For Postdoc
Customers!
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.